KNSA vs. COCO
KNSA (Kiniksa Pharmaceuticals, Ltd.) and COCO (The Vita Coco Company, Inc.) are both stocks. KNSA operates in Biotechnology (Healthcare), while COCO operates in Beverages - Non-Alcoholic (Consumer Defensive). Over the past 3 years, KNSA returned 65.48%/yr vs 42.88%/yr for COCO. At a 0.14 correlation, their price movements are largely independent.
Performance
KNSA vs. COCO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 53.79% return, which is significantly higher than COCO's 34.69% return.
KNSA
- 1D
- -2.97%
- 1M
- 22.99%
- 6M
- 48.68%
- YTD
- 53.79%
- 1Y
- 125.85%
- 3Y*
- 65.48%
- 5Y*
- 34.30%
- 10Y*
- —
COCO
- 1D
- 0.21%
- 1M
- -9.22%
- 6M
- 29.89%
- YTD
- 34.69%
- 1Y
- 92.66%
- 3Y*
- 42.88%
- 5Y*
- —
- 10Y*
- —
KNSA vs. COCO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 53.79% | 108.54% | 12.77% | 17.09% | 27.27% | 8.28% |
COCO The Vita Coco Company, Inc. | 34.69% | 43.62% | 43.90% | 85.60% | 23.72% | -27.33% |
Correlation
The correlation between KNSA and COCO is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.04 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Oct 21, 2021 | 0.14 |
Fundamentals
KNSA:
$4.77B
COCO:
$4.08B
KNSA:
$0.92
COCO:
$1.38
KNSA:
69.30
COCO:
51.88
KNSA:
0.67
COCO:
0.43
KNSA:
6.71
COCO:
6.53
KNSA:
8.63
COCO:
12.26
KNSA:
$754.05M
COCO:
$658.62M
KNSA:
$294.06M
COCO:
$246.32M
KNSA:
$101.06M
COCO:
$100.45M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. COCO — Risk / Return Rank
KNSA
COCO
KNSA vs. COCO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and The Vita Coco Company, Inc. (COCO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KNSA | COCO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.00 | ||
| Sortino ratioReturn per unit of downside risk | +1.27 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.33 | +0.13 |
| Calmar ratioReturn relative to maximum drawdown | 5.67 | 3.98 | +1.69 |
| Martin ratioReturn relative to average drawdown | 20.16 | 10.24 | +9.92 |
Loading charts...
Drawdowns
KNSA vs. COCO - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, which is greater than COCO's maximum drawdown of -56.97%. Use the drawdown chart below to compare losses from any high point for KNSA and COCO.
Loading charts...
Drawdown Indicators
| KNSA | COCO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -56.97% | -26.09% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -23.23% | +2.11% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | -38.55% | +4.41% |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | — | — |
Current DrawdownCurrent decline from peak | -5.72% | -15.02% | +9.30% |
Average DrawdownAverage peak-to-trough decline | -40.34% | -16.72% | -23.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.94% | 9.02% | -3.08% |
Volatility
KNSA vs. COCO - Volatility Comparison
The current volatility for Kiniksa Pharmaceuticals, Ltd. (KNSA) is 14.13%, while The Vita Coco Company, Inc. (COCO) has a volatility of 18.95%. This indicates that KNSA experiences smaller price fluctuations and is considered to be less risky than COCO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | COCO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.13% | 18.95% | -4.82% |
Volatility (6M)Calculated over the trailing 6-month period | 35.91% | 44.60% | -8.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 44.41% | 54.47% | -10.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 53.62% | 56.89% | -3.27% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.89% | 56.89% | +7.00% |
Dividends
KNSA vs. COCO - Dividend Comparison
Neither KNSA nor COCO has paid dividends to shareholders.
Financials
KNSA vs. COCO - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and The Vita Coco Company, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. COCO - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
COCO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, The Vita Coco Company, Inc. reported a gross profit of 71.81M and revenue of 179.77M. Therefore, the gross margin over that period was 40.0%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
COCO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, The Vita Coco Company, Inc. reported an operating income of 33.58M and revenue of 179.77M, resulting in an operating margin of 18.7%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
COCO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, The Vita Coco Company, Inc. reported a net income of 30.47M and revenue of 179.77M, resulting in a net margin of 17.0%.
Frequently Asked Questions
KNSA and COCO have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
COCO has higher volatility (18.95%) compared to KNSA (14.13%). In terms of maximum drawdown, KNSA dropped -83.06% vs COCO's -56.97%.
KNSA currently has the higher Sharpe Ratio (2.70 vs 1.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and COCO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer